Grandem Injection contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron works by blocking serotonin receptors located on vagal nerve terminals and in the chemoreceptor trigger zone of the central nervous system, thereby inhibiting the emetic signals responsible for nausea and vomiting. This injection is indicated for patients undergoing highly emetogenic cancer treatments, providing effective control of acute and delayed phases of emesis. Grandem Injection is administered intravenously, allowing rapid onset of action and improved patient compliance. The dosage and duration of therapy should be individualized based on the emetogenic potential of the treatment regimen and patient response. Common adverse effects may include headache, constipation, and transient elevation of liver enzymes, though the drug is generally well tolerated. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision. Granisetron does not exhibit significant interactions with other antiemetics or chemotherapeutic agents, making it a valuable component in supportive cancer care. Grandem Injection offers a reliable option to enhance patient comfort and adherence during challenging therapeutic protocols.